CAPR Stock Analysis: Buy, Sell, or Hold?
CAPR - Capricor Therapeutics Inc
$29.60
0.26 (0.89%)
▲
5d:
+10.78%
30d:
+0.07%
90d:
-1.66%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Smart Money Accumulation
None View Scanner →
Strength: 6.9/10
Get Alerted When CAPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CAPR shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: CAPR shows positive signals but monitor for confirmation. Market pricing in 0% annual growth which appears achievable. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CAPR is currently trading at $29.60, which is considered extended relative to its 30-day fair value range of $26.38 to $29.28. From a valuation perspective, the stock is trading at a discount (Forward PE: -38.8) compared to its historical average (133.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CAPR is in a strong downtrend. The price is approaching resistance at $30.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CAPR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $54.11 (+82.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CAPR is in a strong downtrend. The price is approaching resistance at $30.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CAPR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $54.11 (+82.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$26.38 -
$29.28
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 82.8% below Wall St target ($54.11)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$26.38 -
$29.28
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$24.65
Resistance Level
$30.19
Current Trend
Strong Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-38.75
Wall Street Target
$54.11
(+82.8%)
Revenue Growth (YoY)
-7.9%
PE vs Historical
-38.8 vs 133.6
CHEAP
Share & Embed Analysis
Last updated: June 23, 2026 9:23 PM ET
Data refreshes hourly during market hours. Next update: 10:23 PM
Data refreshes hourly during market hours. Next update: 10:23 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Karimah Es Sabar
SELL
7529 shares
2026-04-02
Karimah Es Sabar
SELL
53735 shares
2026-04-01
Anthony Bergmann
SELL
25000 shares
2026-03-31
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 61 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
Advanced CAPR Option Strategies
Professional options setups generated by AI based on today's CAPR price and gamma walls.
